Brown Advisory Inc. Sells 437,209 Shares of Bruker Corporation $BRKR

Brown Advisory Inc. lowered its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 15.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,408,012 shares of the medical research company’s stock after selling 437,209 shares during the period. Brown Advisory Inc.’s holdings in Bruker were worth $113,441,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Los Angeles Capital Management LLC bought a new stake in Bruker in the 4th quarter valued at $26,000. Parallel Advisors LLC raised its stake in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock valued at $41,000 after acquiring an additional 479 shares during the period. Allworth Financial LP raised its stake in Bruker by 40.6% in the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Covestor Ltd raised its stake in Bruker by 304.6% in the 4th quarter. Covestor Ltd now owns 1,416 shares of the medical research company’s stock valued at $67,000 after acquiring an additional 1,066 shares during the period. Finally, Parkside Financial Bank & Trust raised its stake in Bruker by 144.6% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock valued at $70,000 after acquiring an additional 876 shares during the period. Institutional investors own 79.52% of the company’s stock.

Bruker Stock Performance

BRKR opened at $54.23 on Monday. The firm has a market cap of $8.26 billion, a P/E ratio of -225.96, a price-to-earnings-growth ratio of 1.74 and a beta of 1.30. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $64.54. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.72 and a current ratio of 1.55. The business’s fifty day moving average is $44.62 and its 200-day moving average is $43.84.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Wednesday, May 6th. The medical research company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $823.40 million for the quarter, compared to analyst estimates of $795.62 million. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.Bruker’s revenue was up 2.7% compared to the same quarter last year. During the same period last year, the firm posted $0.47 earnings per share. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts expect that Bruker Corporation will post 2.12 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd will be given a $0.05 dividend. The ex-dividend date is Monday, June 22nd. This represents a $0.20 annualized dividend and a yield of 0.4%. Bruker’s dividend payout ratio (DPR) is currently -83.33%.

Analysts Set New Price Targets

BRKR has been the topic of a number of research analyst reports. UBS Group increased their price target on Bruker from $40.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Citigroup increased their price target on Bruker from $40.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, May 7th. Guggenheim dropped their price target on Bruker from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Monday, March 30th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. increased their price target on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $51.31.

Insider Buying and Selling

In other Bruker news, VP Mark Munch sold 2,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $39.90, for a total value of $79,800.00. Following the completion of the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $5,124,875.70. This trade represents a 1.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 27.20% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.